Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease,…

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation. CardiolRx is Cardiol’s pure pharmaceutically-produced CBD. Designed to be […]

The post Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation appeared first on Technical420.

Leave a Reply

Your email address will not be published. Required fields are marked *